According to a new report Asia Pacific Companion Diagnostics Market, published by KBV research, the Asia Pacific Companion Diagnostics Market would witness market growth of 21.6% CAGR during the forecast period (2019-2025).
The China market dominated the Asia Pacific Lung Cancer Companion Diagnostics by Country in 2018, growing at a CAGR of 21 % during the forecast period. The Japan market is expected to witness a CAGR of 24.6% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 24.6% during (2019 - 2025).
The Oncology market dominated the South Korea Companion Diagnostics Market by Indication in 2018, growing at a CAGR of 23.6 % during the forecast period. The Neurology market is expected to witness a CAGR of 20.7% during (2019 - 2025).
The Polymerase Chain Reaction (PCR) market dominated the Singapore Companion Diagnostics Market by Technology in 2018, growing at a CAGR of 23.7 % during the forecast period. The Immunohistochemistry market is expected to witness a CAGR of 22.5% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/asia-pacific-companion-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
By Technology
By Indication
By Cancer Type
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
